Palvella intends to use the net proceeds from this offering to support the development of its programs, including QTORIN rapamycin and QTORIN pitavastatin, and for working capital and other general ...
We are very pleased to have aligned with the FDA on the path forward for our MAGNITUDE clinical trial, with measures designed to further enhance patient safety and allow us to continue to investigate ...
About Zevra Therapeutics, Inc. Zevra Therapeutics, Inc. is a purpose-driven, commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases. The company’s ...
(Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the first patient dosed in ...
The stock options are subject to the terms and conditions of Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan, as well as the terms and conditions of the stock option agreement covering the ...
Gleamer’s leadership in routine imaging, and particularly X-ray, is unparalleled through the breadth and scale of its cloud-first AI solutions. DeepHealth, combined with Gleamer’s solutions will ...
Completion of these development activities represents a contractual milestone under the parties’ 2023 development and commercialization agreement focused on non-animal dairy enzymes produced using ...
Enrollment completion in the OCU400 Phase 3 clinical trial combined with positive 3-year data from the Phase 1/2 study are important accomplishments in the Company’s plan to begin bringing this ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, recognizes ...
WILMINGTON, Del., March 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced that it has appointed Prof. Joshua C. Brown, ...
Leerink Partners 2026 Global Healthcare Conference March 8 – 11, 2026, Miami, Florida Fireside Chat: March 11, 8:40 a.m. ET Trevi Representatives: Jennifer Good, President and CEO, and James Cassella, ...
Cash Position: As of December 31, 2025, the Company held $622.5 million in cash, cash equivalents and current investment securities, compared to $367.5 million as of December 31, 2024. The net ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results